Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 219 results for "Byetta"

Human medicines European public assessment report (EPAR): By...

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 2 weeks ago
GLP-1 Receptor Agonists in T2DM -- Guidelines vs Practice General Medicine eJournal, 1 month ago

7 images for Byetta

Virtual Strategy Magazine, 3 weeks ago
Scottrade, 1 month ago
PR Newswire, 1 month ago
Virtual Strategy Magazine, 2 months ago
Virtual Strategy Magazine, 4 months ago
PRWeb, 5 months ago
PR inside, 5 months ago

7 images for Byetta

Logo
Virtual Strategy Magazine, 3 weeks ago
PR Newswire

Legal-Bay Lawsuit Settlement Funding Reports Increase In Number of Filed Cases Involving Byetta (Exenatide) Litigation

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and
 RCL Advisors1 month ago Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available  RCL Advisors2 weeks ago Takeda Pharmaceutical Co. Ltd. Release: Lawsuit Settlement Funding Reports $9 Billion In The First Actos (Pioglitazone) Settlement  BioSpace1 month ago Lawsuit Settlement News Website Announces Launch of Lawsuit Help Center for Mass Tort Plaintiffs  Stock Nod1 month ago
[x]  
PRWeb

Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Establishes Deadlines Pertaining to Discovery, Bernstein Liebhard LLP Reports

Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP ...
 Digital Journal3 weeks ago
[x]  

New and Generic Drug Approvals: Byetta

BYETTA EXENATIDE SYNTHETIC 300MCG/1.2ML (250MCG/ML) INJECTABLE;SUBCUTANEOUS Prescription Yes
 U.S. Food and Drug Administration1 month ago

Forum Post: Leukaemia, Diabetes and Byetta/Exenatide

A group for anyone affected by any type of leukaemia to get together, ask questions, share experiences and support each other. Leukaemia, Diabetes and Byetta/Exenatide Posted by Vegas on 4 Jun 2014 1:43 PM Hi, I was diagnosed with AML last ...
 Macmillan Cancer Support1 month ago Forum Post: RE: Leukaemia, Diabetes and Byetta/Exenatide  Macmillan Cancer Support1 month ago

AstraZeneca Group's (AZN) CEO Pascal Soriot on Q2 2014 Results - Earnings Call Transcript

Pascal Soriot Good afternoon, everybody. I'm Pascal Soriot and I'm joined today by Briggs Morrison, our EVP of Global Medicines Development and our Chief Medical Officer. I also have with me Marc Dunoyer, our CFO; Mene Pangalos, our EVP of ...
 Seeking Alpha3 hours ago

Express Scripts Plans to Narrow Specialty Drugs List Further

Reuters Health Information By Bill Berkrot July31,2014 (Reuters) - Express Scripts Holding, the largest U.S. pharmacy benefit manager, expects to exclude more expensive specialty drugs from its list of preferred medicines next year, the latest ...
 Medscape14 hours ago
Pharma Letter

AstraZeneca 2nd-qtr earnings leap, beating expectations

Anglo-Swedish pharma major AstraZeneca (LSE: AZN), which earlier this year defended itself against an unsolicited takeover attempt by Pfizer, this morning reported second-quarter 2014 financials that beat analysts forecasts and surprised investors ...
 Pharma Letter15 hours ago
Jutia Group

Second Quarter & Half Year Results 2014

SECOND Quarter AND HALF YEAR Results 2014 Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms. ยท Brilinta: +84%, with continued ...
 TrustNet23 hours ago Company Update (NYSE:BMY): European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE  Jutia Group2 days ago Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results  Jutia Group1 week ago Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb to Announce Results for Second Quarter on July 24  Jutia Group1 month ago

Ziopharm: Pipeline Expansion And Data Updates To Drive Near-Term Upside

Summary There are many catalysts ahead with new data on many fronts and recent hints at what to expect from new INDs to be revealed starting at year end. One should not necessarily depend on any one catalyst to launch the share price higher but a ...
 Seeking Alpha2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less